CYTK Cytokinetics, Incorporated - Common Stock
NASDAQ · Biotechnology · Voir sur SEC EDGAR ↗ clôture Oct 2, 2026 10-K/10-Q Aoû 6, 2026
$65,60
· % de la fourchette 52 sem.
· au-dessus du plus bas
· vers le haut
$54,30Bas 52 semaines
$88,31Haut 52 semaines
Capitalisation Boursière
$8.07B
P/E (TTM)
-9.1
BPA (TTM)
$-7.23
Revenu (TTM)
$68M
vos badges
Fourchette 52 semaines
$54–$88
Note des analystes
BUY
Objectif de cours
$110
P/E
-9.1
ROE
329.8%
Marge nette
-1321.1%
Votre barre de badges est vide — épinglez une métrique n'importe où sur cette page.
CYTK Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$65.60
Capitalisation Boursière
$8.07B
P/E (TTM)
-9.1
BPA (TTM)
$-7.23
Revenu (TTM)
$68M
ROE (TTM)
329.8%
Dette/Capitaux propres (MRQ)
-1.6
Fourchette 52 semaines
$54–$88
CYTK Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
fourchette
barres
La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.
Splits d'actions
| Date ex-dividende | Division | Type |
|---|---|---|
| 25 juin 2013 | 1-for-6 | Inverse |
À propos de Cytokinetics, Incorporated - Common Stock Présentation de l'entreprise depuis Wikipedia
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
secteurHealthcare
industrieBiotechnology
employés673
paysUS
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenu$88M2016-12-31 → 2025-12-31
BPA$-6.542016-12-31 → 2025-12-31
Flux de trésorerie libre$-535M2016-12-31 → 2025-12-31
Marge nette-1321.1%2016-12-31 → 2025-12-31
Valorisation et Ratios
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
| Métrique | Tendance sur 5 ans | CYTK | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -9.1moyenne 5 ans ≈-12.2 | ≈-12.2 | · | · | |
| P/S | 91.6moyenne 5 ans ≈323.5 | ≈323.5 | 41.9 | Surévalué | |
| P/B | -12.2moyenne 5 ans ≈-19.9 | ≈-19.9 | · | · | |
| EV / EBITDA | -13.7moyenne 5 ans ≈-15.1 | ≈-15.1 | · | · | |
| Price / FCF (Cours / FCF) | -15.1moyenne 5 ans ≈-16.6 | ≈-16.6 | · | · | |
| Price / Cash Flow (Cours / Flux de trésorerie) | -15.8moyenne 5 ans ≈-18.3 | ≈-18.3 | · | · | |
| EV / Revenue (VE / Chiffre d'affaires) | 93.5moyenne 5 ans ≈322.6 | ≈322.6 | · | · | |
| EV / FCF (VE / FCF) | -15.4moyenne 5 ans ≈-16.6 | ≈-16.6 | · | · |
La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
| Métrique | Tendance sur 5 ans | CYTK | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Marge d'exploitation (TTM) | -1046.1%moyenne 5 ans ≈-2159.0% | ≈-2159.0% | -118.4% | Faible | |
| Marge EBITDA (TTM) | -1027.6%moyenne 5 ans ≈-2113.0% | ≈-2113.0% | -118.4% | Faible | |
| Marge nette (TTM) | -1321.1%moyenne 5 ans ≈-2357.7% | ≈-2357.7% | -176.2% | Faible | |
| ROA (TTM) | -56.8%moyenne 5 ans ≈-47.8% | ≈-47.8% | -22.9% | Faible | |
| ROE (TTM) | 329.8%moyenne 5 ans ≈322.1% | ≈322.1% | -13.2% | Premier rang |
Santé financière Dette, liquidité, solvabilité — solidité du bilan
| Métrique | Tendance sur 5 ans | CYTK | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Dette / Capitaux propres (MRQ) | -1.6moyenne 5 ans ≈-0.4 | ≈-0.4 | 0.3 | Faible endettement | |
| Ratio de liquidité (MRQ) | 6.7moyenne 5 ans ≈6.7 | ≈6.7 | 5.9 | En ligne | |
| Quick Ratio (Ratio de liquidité réduite) | 0.7moyenne 5 ans ≈1.1 | ≈1.1 | 3.6 | Faible liquidité | |
| Dette à long terme / Capitaux propres (MRQ) | -1.4moyenne 5 ans ≈-0.3 | ≈-0.3 | · | · | |
| Interest Coverage (Ratio de couverture des intérêts) | -13.4moyenne 5 ans ≈-14.6 | ≈-14.6 | -7.7 | Faible liquidité |
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
| Métrique | Tendance sur 5 ans | CYTK | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Revenue YoY (Chiffre d'affaires YoY) | 376.6%moyenne 5 ans ≈98.1% | ≈98.1% | · | · | |
| Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans) | -2.4%moyenne 5 ans ≈-29.0% | ≈-29.0% | · | · | |
| Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans) | 9.5% | · | · | · |
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
| Métrique | Tendance sur 5 ans | CYTK | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Asset Turnover (Rotation des actifs) | 0.1moyenne 5 ans ≈0.1 | ≈0.1 | 0.2 | Faible | |
| Receivables Turnover (Rotation des créances) | 5.1moyenne 5 ans ≈4.8 | ≈4.8 | 5.7 | En ligne | |
| Revenue / Employee (Chiffre d'affaires annuel ÷ employés (effectif déclaré, yfinance). Dérivé — pas un concept SEC-XBRL stocké.) | ≈$130.8K | · | · | · |
valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
-4.4%
Prochain rapport
Nov 03, 2026
| Période | Rapport | EPS Actual | BPA est. | Surprise |
|---|---|---|---|---|
| 30 juin 2026 | Aoû 5, 2026 | $-1.50 | $-1.67 | 10.4% |
| 31 mars 2026 | $-1.67 | $-1.69 | 0.94% | |
| 31 décembre 2025 | $-1.50 | $-1.49 | -0.97% | |
| 30 septembre 2025 | $-2.55 | $-1.61 | -58.2% | |
| 30 juin 2025 | $-1.12 | $-1.41 | 20.3% | |
| 31 mars 2025 | $-1.39 | $-1.41 | 1.4% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Bilan
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Flux de trésorerie
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Rentabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Liquidité et Solvabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Efficacité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Par action
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-5.37 | $-1.15 | $-3.80 | $-1.14 | $2.88 | $1.60 | $-0.18 | $0.47 | $2.04 | $2.32 | $1.73 | $2.38 | |
| Revenue / Share | $733.03 | $164.98 | $78.01 | $1053.03 | · | · | · | · | $0.27 | $2.50 | · | · | |
| Cash Flow / Share | $-4246.43 | $-3535.39 | $-4292.54 | $-3334.44 | · | · | · | · | $-2.06 | $0.87 | · | · | |
| Cash / Share | $1.00 | $0.80 | $1.11 | $0.69 | $1.33 | $1.17 | $0.62 | $0.77 | $2.32 | $1.65 | $1.64 | $0.52 | |
| EPS (TTM) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 |
Taux de croissance
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM)
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Compte de résultat
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Bilan
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Flux de trésorerie
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Rentabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Liquidité et Solvabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Efficacité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Par action
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $216.71 | $157.01 | · | $16.14 | $558.94 | $13.33 | · | $3.93 | $2.28 | $8.19 | · | $3.93 | $9.05 | $48.47 | · | $26.82 | |
| Cash Flow / Share | · | $-1179.96 | · | · | · | $-1110.73 | · | · | · | $-1270.62 | · | · | · | $-1285.00 | · | · | |
| EPS (TTM) | $-7.23 | $-6.85 | · | $-6.29 | $-5.10 | $-5.29 | · | $-5.38 | $-5.37 | $-5.40 | · | $-5.60 | $-5.77 | $-4.66 | · | $-3.12 |
Valorisation (TTM)
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $68M | $106M | · | $87M | $86M | $19M | · | $3M | $3M | $4M | · | $8M | $10M | $98M | · | $148M | |
| Net Income TTM | $-894M | $-830M | · | $-752M | $-606M | $-615M | · | $-576M | $-545M | $-531M | · | $-527M | $-540M | $-431M | · | $-282M | |
| P/E | -11.8 | -9.6 | · | -8.7 | -6.5 | -7.6 | · | -9.8 | -10.1 | -13.0 | · | -5.3 | -5.7 | -7.6 | · | -15.5 | |
| Earnings Yield | -8.5% | -10.4% | · | -11.4% | -15.4% | -13.2% | · | -10.2% | -9.9% | -7.7% | · | -19.0% | -17.7% | -13.2% | · | -6.4% |
Période la plus récente à gauche · valeurs nulles affichées comme ·
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenu | $88M | $18M | $8M | $95M | $70M |
| Marge d'exploitation % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Résultat net | $-785M | $-590M | $-526M | $-389M | $-215M |
| BPA dilué | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dette / Capitaux propres | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Ratio de liquidité | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Ratio de liquidité réduite | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $-535M | $-400M | $-416M | $-311M | $-191M |
Détenteurs institutionnels (13F) 535 déclarants · $13.2B total · Au 30 septembre 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Détenteurs
535
Valeur détenue
$13.2B
Nouvelles positions
95
Positions clôturées
49
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 95 (-11 vs T. préc.) | 49 (-7 vs T. préc.) | 238 (+49 vs T. préc.) | 113 (-29 vs T. préc.) | +10.8M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $1 711 838 738 | 20 094 362 | 12,99% | Actions |
| VANGUARD GROUP INC | $765 538 243 | 12 048 131 | 5,81% | Actions |
| WELLINGTON MANAGEMENT GROUP LLP | $590 517 486 | 6 931 770 | 4,48% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571 778 157 | 6 711 799 | 4,34% | Actions |
| STATE STREET CORP | $553 243 709 | 6 494 233 | 4,20% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $521 151 103 | 6 117 515 | 3,95% | Actions |
| FMR LLC | $428 657 534 | 5 031 782 | 3,25% | Actions |
| Avoro Capital Advisors LLC | $425 949 915 | 4 999 999 | 3,23% | Actions |
| BANK OF AMERICA CORP /DE/ | $394 916 049 | 4 635 709 | 3,00% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $316 325 896 | 3 712 501 | 2,40% | Actions |
| RTW INVESTMENTS, LP | $243 814 036 | 2 862 003 | 1,85% | Actions |
| Polar Capital Holdings Plc | $191 988 358 | 2 253 649 | 1,46% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161 060 214 | 1 890 600 | 1,22% | Option d'achat |
| GOLDMAN SACHS GROUP INC | $150 069 725 | 1 761 588 | 1,14% | Actions |
| Capital Research Global Investors | $143 683 584 | 1 686 625 | 1,09% | Actions |
| NORTHERN TRUST CORP | $140 337 319 | 1 647 345 | 1,06% | Actions |
| JPMORGAN CHASE & CO | $139 150 046 | 1 588 895 | 1,06% | Actions |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136 597 224 | 1 603 442 | 1,04% | Actions |
| Integral Health Asset Management, LLC | $136 304 000 | 1 600 000 | 1,03% | Actions |
| Point72 Asset Management, L.P. | $135 257 185 | 1 587 712 | 1,03% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133 388 883 | 1 565 781 | 1,01% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131 998 327 | 1 549 458 | 1,00% | Actions |
| ARMISTICE CAPITAL, LLC | $130 340 700 | 1 530 000 | 0,99% | Option d'achat |
| MORGAN STANLEY | $128 664 004 | 1 510 318 | 0,98% | Actions |
| PRINCIPAL FINANCIAL GROUP INC | $111 740 656 | 1 311 664 | 0,85% | Actions |
| Capital International Investors | $111 245 191 | 1 305 848 | 0,84% | Actions |
| Invesco Ltd. | $105 237 167 | 1 235 323 | 0,80% | Actions |
| ARMISTICE CAPITAL, LLC | $102 342 325 | 1 201 342 | 0,78% | Actions |
| UBS Group AG | $99 781 940 | 1 171 287 | 0,76% | Actions |
| Pictet Asset Management Holding SA | $99 038 455 | 1 160 463 | 0,75% | Actions |
| Frazier Life Sciences Management, L.P. | $98 810 092 | 1 159 879 | 0,75% | Actions |
| Bank of New York Mellon Corp | $98 027 901 | 1 150 697 | 0,74% | Actions |
| Holocene Advisors, LP | $97 506 685 | 1 144 579 | 0,74% | Actions |
| Woodline Partners LP | $93 769 315 | 1 100 708 | 0,71% | Actions |
| D. E. Shaw & Co., Inc. | $89 287 894 | 1 048 103 | 0,68% | Actions |
| NORGES BANK | $86 512 319 | 1 015 522 | 0,66% | Actions |
| Royalty Pharma Sub-Manager, LLC | $83 519 594 | 980 392 | 0,63% | Actions |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81 937 000 | 961 815 | 0,62% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $77 218 175 | 906 423 | 0,59% | Actions |
| CITADEL ADVISORS LLC | $77 062 874 | 904 600 | 0,58% | Option d'achat |
| FRANKLIN RESOURCES INC | $75 911 721 | 891 087 | 0,58% | Actions |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $70 521 134 | 827 810 | 0,53% | Actions |
| Melqart Asset Management (UK) Ltd | $65 385 455 | 767 525 | 0,50% | Actions |
| Siren, L.L.C. | $64 655 121 | 758 952 | 0,49% | Actions |
| Fisher Asset Management, LLC | $63 355 547 | 743 697 | 0,48% | Actions |
| Foresite Capital Management IV, LLC | $60 884 867 | 714 695 | 0,46% | Actions |
| Balyasny Asset Management L.P. | $60 599 821 | 711 349 | 0,46% | Actions |
| Deep Track Capital, LP | $59 633 000 | 700 000 | 0,45% | Actions |
| JANE STREET GROUP, LLC | $59 633 000 | 700 000 | 0,45% | Option d'achat |
| BNP PARIBAS FINANCIAL MARKETS | $58 702 470 | 689 077 | 0,45% | Actions |
Initiés de la société 52 initiés · 19 dirigeants · 23 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Robert I Blum | President & CEO | 28 septembre 2026 M | 278 544 | 0 | 20 | $-17 291 957 |
| Sung Lee | EVP, Chief Financial Officer | 1 juillet 2026 M | 63 221 | 0 | 5 | $-5 695 855 |
| Ching Jaw | SVP Finance & CFO | 6 mars 2023 A | 87 346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 28 février 2017 F | 40 323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 22 septembre 2026 M | 153 902 | 0 | 21 | $-4 654 735 |
| Andrew Callos | EVP, Chief Commercial Officer | 31 août 2026 M | 58 555 | 0 | 25 | $-16 021 293 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 15 mars 2026 A | 107 943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 3 décembre 2024 A | 18 655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 30 août 2024 A | 33 140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 15 mars 2022 M | 103 408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 7 mars 2022 F | 153 233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 27 février 2018 A | 32 548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 27 février 2018 A | 21 520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 31 août 2017 M | 46 441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 28 février 2017 A | 29 004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 28 février 2017 A | 47 255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 28 février 2011 A | 42 000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 18 décembre 2009 M | 20 043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 29 février 2008 A | 47 896 | 0 | 0 | $0 |
| Robert E Landry | Administrateur | 15 septembre 2026 S | 8 184 | 0 | 2 | $-146 790 |
| Lynne B Parshall | Administrateur | 1 septembre 2026 S | 10 784 | 0 | 4 | $-1 357 500 |
| Robert Arthur Harrington | Administrateur | 15 juillet 2026 A | 21 932 | 0 | 1 | $-143 620 |
| James M Daly | Administrateur | 15 juillet 2026 A | 3 390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Administrateur | 15 juillet 2026 A | 10 434 | 0 | 4 | $-2 837 811 |
| Nancy Wysenski | Administrateur | 15 juillet 2026 A | 33 992 | 0 | 0 | $0 |
| Wendell Wierenga | Administrateur | 15 juillet 2026 A | 35 563 | 0 | 3 | $-1 881 925 |
| John T Henderson | Administrateur | 15 juillet 2026 A | 78 360 | 0 | 2 | $-2 078 525 |
| Muna Bhanji | Administrateur | 27 mai 2026 A | 26 361 | 0 | 0 | $0 |
| Wendall Wierenga | Administrateur | 15 juillet 2025 A | 32 345 | 0 | 0 | $0 |
| COSTA SANTO J | Administrateur | 15 mai 2024 A | 20 600 | 0 | 0 | $0 |
| Sandford D Smith | Administrateur | 2 janvier 2024 A | 18 801 | 0 | 0 | $0 |
| Robert Califf | Administrateur | 3 janvier 2022 A | 6 003 | 0 | 0 | $0 |
| GAGE L PATRICK | Administrateur | 8 novembre 2021 M | 28 932 | 0 | 0 | $0 |
| Denise Gilbert | Administrateur | 20 mai 2015 J | · | 0 | 0 | $0 |
| Stephen M Dow | Administrateur | 2 janvier 2013 A | 1 421 052 | 0 | 0 | $0 |
| James A Spudich | Administrateur | 18 mai 2011 A | 180 600 | 0 | 0 | $0 |
| Grant A Heidrich III | Administrateur | 3 janvier 2011 A | 93 755 | 0 | 0 | $0 |
| Michael Schmertzler | Administrateur | 3 juin 2010 S | 4 340 923 | 0 | 0 | $0 |
| Mark Mcdade | Administrateur | 21 mai 2009 A | · | 0 | 0 | $0 |
| Charles J Homcy | Administrateur | 22 mai 2008 A | · | 0 | 0 | $0 |
| William J Rutter | Administrateur | 29 avril 2004 C | 172 413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | Détenteur de 10% | 29 avril 2004 C | 1 615 716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | Détenteur de 10% | 29 avril 2004 C | 771 052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | Détenteur de 10% | 29 avril 2004 C | 650 000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | Détenteur de 10% | 29 avril 2004 C | 755 631 | 0 | 0 | $0 |
| Elisabeth Schnieders | · | 28 février 2017 A | 43 919 | 0 | 0 | $0 |
| James H Sabry | · | 3 juin 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | · | 29 avril 2004 C | 24 050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | · | 29 avril 2004 C | 625 950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | · | 29 avril 2004 C | 1 742 951 | 0 | 0 | $0 |
| SEVIN ROSEN VIII AFFILIATES FUND LP | · | 29 avril 2004 C | 15 421 | 0 | 0 | $0 |
| SEVIN ROSEN VI AFFILIATES FUND LP | · | 29 avril 2004 C | 127 235 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Détention d'ETF Détenu par 54 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,51% | 19 346 NS | 31 juillet 2026 | N-PORT |
| XMMO · Invesco Exchange-Traded Fund Trust | 0,81% | 882 597 SH | 2 octobre 2026 | Quotidien |
| LABU · Direxion Shares ETF Trust | 0,79% | 50 312 NS | 31 juillet 2026 | N-PORT |
| IBB · iShares Trust | 0,73% | 1 020 305 SH | 11 septembre 2026 | Quotidien |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,72% | 53 872 NS | 31 juillet 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,64% | 107 023 NS | 31 juillet 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,64% | 102 933 SH | 19 août 2026 | Quotidien |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,61% | 9 831 SH | 2 octobre 2026 | Quotidien |
| IQSM · New York Life Investments ETF Trust | 0,35% | 14 748 NS | 31 juillet 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,34% | 761 130 SH | 19 août 2026 | Quotidien |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 72 343 SH | 19 août 2026 | Quotidien |
| RSSL · Global X Funds | 0,33% | 63 327 NS | 31 juillet 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,32% | 1 797 986 SH | 19 août 2026 | Quotidien |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,32% | 219 413 SH | 19 août 2026 | Quotidien |
| IWM · iShares Trust | 0,32% | 3 378 753 SH | 11 septembre 2026 | Quotidien |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,31% | 53 623 SH | 19 août 2026 | Quotidien |
| ISCG · iShares Trust | 0,30% | 39 366 SH | 11 septembre 2026 | Quotidien |
| PTMC · Pacer Funds Trust | 0,29% | 14 892 NS | 31 juillet 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,27% | 48 364 NS | 31 juillet 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,24% | 20 179 NS | 31 juillet 2026 | N-PORT |
| ESML · iShares Trust | 0,23% | 88 671 SH | 11 septembre 2026 | Quotidien |
| MIDU · Direxion Shares ETF Trust | 0,22% | 1 994 NS | 31 juillet 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,22% | 687 NS | 31 juillet 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,22% | 16 176 NS | 31 juillet 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,21% | 54 306 NS | 31 juillet 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0,20% | 15 469 NS | 31 juillet 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,19% | 3 254 NS | 31 juillet 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,17% | 40 586 SH | 19 août 2026 | Quotidien |
| VB · VANGUARD INDEX FUNDS | 0,14% | 3 113 794 SH | 19 août 2026 | Quotidien |
| VHT · VANGUARD WORLD FUND | 0,14% | 333 056 SH | 19 août 2026 | Quotidien |
| VXF · VANGUARD INDEX FUNDS | 0,13% | 1 557 779 SH | 19 août 2026 | Quotidien |
| FHLC · FIDELITY COVINGTON TRUST | 0,12% | 52 671 NS | 31 juillet 2026 | N-PORT |
| ESSC · Strategy Shares | 0,10% | 466 NS | 31 juillet 2026 | N-PORT |
| WSML · iShares Trust | 0,09% | 7 841 SH | 11 septembre 2026 | Quotidien |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,07% | 15 233 SH | 19 août 2026 | Quotidien |
| IWO · iShares Trust | 0,07% | 133 196 SH | 11 septembre 2026 | Quotidien |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,07% | 27 265 SH | 2 octobre 2026 | Quotidien |
| TILT · FlexShares Trust | 0,02% | 5 740 NS | 31 juillet 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 4 315 260 SH | 19 août 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 10 880 SH | 19 août 2026 | Quotidien |
| ESGV · VANGUARD WORLD FUND | 0,02% | 29 174 SH | 19 août 2026 | Quotidien |
| IUSG · iShares Trust | 0,01% | 64 511 SH | 11 septembre 2026 | Quotidien |
| IUSV · iShares Trust | 0,01% | 53 197 SH | 11 septembre 2026 | Quotidien |
| ITOT · iShares Trust | 0,01% | 180 021 SH | 11 septembre 2026 | Quotidien |
| IWV · iShares Trust | 0,01% | 36 083 SH | 10 septembre 2026 | Quotidien |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 106 638 SH | 19 août 2026 | Quotidien |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,00% | 478 SH | 29 septembre 2026 | Quotidien |
| IJH · iShares Trust | · | 4 763 860 SH | 11 septembre 2026 | Quotidien |
| IJK · iShares Trust | · | 425 186 SH | 11 septembre 2026 | Quotidien |
| IJJ · iShares Trust | · | 318 457 SH | 21 août 2026 | Quotidien |
| IWN · iShares Trust | · | 1 107 696 SH | 11 septembre 2026 | Quotidien |
| XJH · iShares Trust | · | 18 548 SH | 8 septembre 2026 | Quotidien |
| ISCB · iShares Trust | · | 5 565 SH | 11 septembre 2026 | Quotidien |
| SMLF · iShares Trust | · | 71 881 SH | 11 septembre 2026 | Quotidien |
CYTK Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
notation · 28 analystes
ACHAT
Objectif médian
$107.50
+63,9%
6 21,4%
Achat fort
19 67,9%
Achat
3 10,7%
Conserver
0 0,0%
Vente
0 0,0%
Vente forte
Objectif de cours à 12 mois
20 analystes · 2026-09-29Objectif moyen $109.90 +67,5%
← En dessous de tous les objectifs
Prix actuel $65.60
Bas$85.00
Moyenne$109.90
Haut$146.00
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | · |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | · |
| PCVX | $6.05B | -8.2 | · | · | -26.6% | · |
| TGTX | $4.63B | 10.8 | 87.3% | 72.6% | 96.7% | · |
| SYRE | $2.56B | 10.1 | -62.0% | · | -26.5% | · |
| PRAX | $7.43B | -21.9 | 249.5% | · | -47.3% | · |
Dernières actualités Actualités récentes mentionnant cette entreprise
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Source : Dépôt SEC 10-Q le Aoû 6, 2026